Comparative Pharmacology
Head-to-head clinical analysis: STAXYN versus STENDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STAXYN versus STENDRA.
STAXYN vs STENDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). By inhibiting PDE5, sildenafil increases intracellular cGMP levels in the corpus cavernosum, enhancing the relaxant effect of nitric oxide (NO) on smooth muscle cells, thereby facilitating penile erection in response to sexual stimulation.
Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation in corpus cavernosum, leading to smooth muscle relaxation and increased penile blood flow.
10 mg sublingually as needed, 30–60 minutes before sexual activity. Maximum 1 dose per 24 hours.
50 mg orally once daily as needed, 1 hour before sexual activity. Maximum dose 100 mg. Maximum frequency once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 hours; clinically, no accumulation with once-daily dosing
Terminal elimination half-life is approximately 4 hours in healthy subjects; may be prolonged in hepatic impairment (Child-Pugh B: up to 6 hours) or with concomitant CYP3A4 inhibitors.
Renal (approximately 90% as metabolites, <2% unchanged); fecal (10%)
Fecal (approximately 63%) and renal (approximately 21%) as metabolites; less than 2% excreted unchanged in urine.
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor